Plain-English translation of NCT04269902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether starting treatment with and immediately after diagnosis helps people with high-risk chronic lymphocytic leukemia live longer than waiting to start the same medications later. The study will compare two groups: one that begins treatment as soon as they qualify, and another that waits to start treatment until certain disease markers indicate it's necessary.
Doctors don't yet know whether people with this type of blood cancer benefit from starting treatment right away when they have no symptoms, or whether waiting until symptoms appear is just as good. This study aims to answer that question and help guide treatment decisions for future patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either start treatment immediately or wait until your doctor determines it's necessary. Either way, you'll receive the same two medications given as injections and pills over 12 monthly cycles. Throughout the study, you'll have regular visits for blood tests, imaging scans, and bone marrow biopsies to monitor how well the treatment is working. The study will follow you for several years to see how long you survive and how your quality of life is affected.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States